Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.88USD
24 Apr 2017
Change (% chg)

$0.05 (+6.28%)
Prev Close
$0.83
Open
$0.82
Day's High
$0.90
Day's Low
$0.81
Volume
41,201
Avg. Vol
52,802
52-wk High
$5.97
52-wk Low
$0.66

Latest Key Developments (Source: Significant Developments)

Trovagene reports Q4 loss per share $0.34
Wednesday, 15 Mar 2017 04:04pm EDT 

Trovagene Inc : Trovagene reports fourth quarter and year end 2016 financial results . Q4 loss per share $0.34 . Q4 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S . Trovagene Inc - estimates restructuring program will reduce annual pre-tax expenses by approximately $8.0 million per year .Trovagene - Restructuring program includes reduction of about 30 personnel and expenses primarily linked to research, clinical studies and operations.  Full Article

Trovagene, Nerviano announce license agreement for therapeutic candidate PCM-075
Wednesday, 15 Mar 2017 04:02pm EDT 

Trovagene Inc : Trovagene and Nerviano announce license agreement for therapeutic candidate PCM-075 . Trovagene Inc says Trovagene will assume sole responsibility for global development and commercialization of pcm-075 . Trovagene Inc- under terms of license agreement, trovagene will assume sole responsibility for global development and commercialization of pcm-075 . Trovagene inc says Nerviano will receive an upfront payment of $2.0 million, as well as development and regulatory-based milestone payments . Trovagene Inc - co, Nerviano medical sciences signed agreement grants co exclusive global development and commercialization rights to nms-1286937 . Trovagene Inc says Nerviano will also receive royalty payments on future net sales of PCM-075 .Trovagene Inc - Trovagene plans to develop PCM-075 initially in aml.  Full Article

Trovagene to accelerate global distribution of liquid biopsy technology
Tuesday, 13 Dec 2016 04:05pm EST 

Trovagene Inc : Estimates program will reduce annual pre-tax expenses by about $4.0m per year mainly through reduction of about 20 personnel and expenses .Announces a reorganization to accelerate global distribution of liquid biopsy technology.  Full Article

Trovagene and Boreal Genomics announce strategic partnership
Wednesday, 30 Nov 2016 08:00am EST 

Trovagene Inc : Press release - Trovagene and Boreal Genomics announce strategic partnership .Trovagene - co, boreal have contributed technology to enhance ctdna detection capabilities to develop series of multigene panels planned for launch in 2017.  Full Article

Trovagene reports Q2 loss per share $0.34
Thursday, 4 Aug 2016 04:15pm EDT 

Trovagene Inc : Q2 loss per share $0.34 . Trovagene reports second quarter 2016 financial results and accomplishments .Q2 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

Trovagene entered into Fifth amendment to loan and security agreement with Oxford Finance, Silicon Valley Bank
Tuesday, 26 Jul 2016 04:32pm EDT 

Trovagene Inc : On July 20, 2016, Co entered into Fifth amendment to loan and security agreement with Oxford Finance LLC, Silicon Valley Bank .Maturity date of loan was amended to february 1, 2020 - sec filing.  Full Article

Trovagene files for mixed shelf of up to $250 million
Friday, 27 May 2016 05:23pm EDT 

Trovagene Inc :Files for mixed shelf of up to $250 million - SEC filing.  Full Article

Trovagene Q1 loss per share $0.36
Tuesday, 10 May 2016 04:49pm EDT 

Trovagene Inc : Trovagene announces first quarter 2016 financial results . Q1 loss per share $0.36 .Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.  Full Article

Trovagene Inc enters into preferred provider agreement with Multiplan Inc
Tuesday, 1 Mar 2016 08:15am EST 

Trovagene Inc:Entered into an agreement with Multiplan Inc for participation in PHCS, Multiplan and Beech Street Networks.  Full Article

Trovagene Inc announces closing of public offering of common stock
Wednesday, 22 Jul 2015 10:12am EDT 

Trovagene Inc:Closing of its previously announced underwritten public offering.Says sold 4,600,000 shares of its common stock in the offering.Offering price was $8.75 per share and gross proceeds to Trovagene are approximately $40.3 million.Intends to use the net proceeds from this offering to fund its research and development activities and for working capital and other general corporate purposes.Piper Jaffray & Co. and Leerink Partners LLC are acting as joint book-running managers for the offering.Janney Montgomery Scott LLC, Cantor Fitzgerald & Co. and Maxim Group LLC are acting as co-managers for the offering.  Full Article

More From Around the Web

BRIEF-Trovagene reports Q4 loss per share $0.34

* Trovagene reports fourth quarter and year end 2016 financial results